HomeCompareEIGR vs EPRT

EIGR vs EPRT: Dividend Comparison 2026

EIGR yields 115.94% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EIGR wins by $7.26M in total portfolio value
10 years
EIGR
EIGR
● Live price
115.94%
Share price
$1.73
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.32M
Annual income
$2,715,715.87
Full EIGR calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — EIGR vs EPRT

📍 EIGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGREPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGR + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGR pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGR
Annual income on $10K today (after 15% tax)
$9,855.07/yr
After 10yr DRIP, annual income (after tax)
$2,308,358.49/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EIGR beats the other by $2,297,443.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGR + EPRT for your $10,000?

EIGR: 50%EPRT: 50%
100% EPRT50/50100% EIGR
Portfolio after 10yr
$3.69M
Annual income
$1,364,278.30/yr
Blended yield
36.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

EIGR
Analyst Ratings
11
Buy
Consensus: Buy
Altman Z
-24.5
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGR buys
0
EPRT buys
0
No recent congressional trades found for EIGR or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGREPRT
Forward yield115.94%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$7.32M$63.4K
Annual income after 10y$2,715,715.87$12,840.73
Total dividends collected$6.64M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: EIGR vs EPRT ($10,000, DRIP)

YearEIGR PortfolioEIGR Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$22,294$11,594.20$11,205$505.18+$11.1KEIGR
2$48,012$24,157.34$12,672$682.46+$35.3KEIGR
3$99,994$48,621.05$14,490$930.48+$85.5KEIGR
4$201,631$94,637.59$16,786$1,282.69+$184.8KEIGR
5$394,091$178,346.07$19,753$1,791.56+$374.3KEIGR
6$747,454$325,775.96$23,677$2,541.64+$723.8KEIGR
7$1,377,237$577,460.92$29,008$3,672.99+$1.35MEIGR
8$2,468,047$994,404.26$36,463$5,425.08+$2.43MEIGR
9$4,306,232$1,665,421.46$47,238$8,221.57+$4.26MEIGR
10$7,323,384$2,715,715.87$63,385$12,840.73+$7.26MEIGR

EIGR vs EPRT: Complete Analysis 2026

EIGRStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Full EIGR Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this EIGR vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGR vs SCHDEIGR vs JEPIEIGR vs OEIGR vs KOEIGR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.